Kentucky Retirement Systems Reduces Position in Edwards Lifesciences Corporation $EW

Kentucky Retirement Systems reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 75.0% in the 1st quarter, HoldingsChannel.com reports. The firm owned 9,033 shares of the medical research company’s stock after selling 27,102 shares during the quarter. Kentucky Retirement Systems’ holdings in Edwards Lifesciences were worth $723,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $25,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $27,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $28,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW opened at $86.17 on Friday. The company has a 50-day moving average of $87.91 and a two-hundred day moving average of $83.89. The stock has a market cap of $49.62 billion, a price-to-earnings ratio of 49.52, a PEG ratio of 2.18 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on EW. Evercore reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Mizuho lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,558 shares of company stock valued at $3,770,939 in the last three months. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.